<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04009941</url>
  </required_header>
  <id_info>
    <org_study_id>BC-P26</org_study_id>
    <nct_id>NCT04009941</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of 4.5mg PEG-rhG-CSF Per Cycle in Preventing Neutropenia After Intensive Chemotherapy for Breast Cancer</brief_title>
  <official_title>Study on the Efficacy and Safety of 4.5mg Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Per Cycle in Preventing Neutropenia After Intensive Chemotherapy for Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, single-center, single-arm clinical study, to evaluate the clinical
      efficacy, safety and tolerance of patients with early breast cancer receiving ddEC adjuvant
      chemotherapy, accepting PEG-rhG-CSF as primary prevention of neutropenia.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2019</start_date>
  <completion_date type="Anticipated">May 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>RDI for each EC chemotherapy</measure>
    <time_frame>60 days after the first chemotherapy</time_frame>
    <description>Ratio of actual dose intensity to standard dose intensity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Chemotherapeutic dose adjustment due to neutropenia</measure>
    <time_frame>60 days after the first chemotherapy</time_frame>
    <description>percentage of dose decreasing due to neutropenia</description>
  </primary_outcome>
  <primary_outcome>
    <measure>overall completion rate of chemotherapy</measure>
    <time_frame>60 days after the first chemotherapy</time_frame>
    <description>calculate the overall chemo-completion rate among all patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of febrile neutropenia</measure>
    <time_frame>60 days after the first chemotherapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Grade 3/4 ACN reduction</measure>
    <time_frame>60 days after the first chemotherapy</time_frame>
    <description>evaluate the incidence of Grade 3/4 absolute neutrophil count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Grade 3/4 ACN reduction</measure>
    <time_frame>60 days after the first chemotherapy</time_frame>
    <description>observe the duration of Grade 3/4 absolute neutrophil count</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Neutropenia</condition>
  <arm_group>
    <arm_group_label>PEG-rhG-CSF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with breast cancer who were treated with intensive chemotherapy received PEG-rhG-CSF.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PEG-rhG-CSF</intervention_name>
    <description>4.5mg per cycle, 24 hours after chemotherapy</description>
    <arm_group_label>PEG-rhG-CSF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Breast cancer patients in need for adjuvant chemotherapy confirmed by histopathology,
             whom should accept ddEC regimen.

          -  ECOG&lt;=1

          -  Expected survival is greater than 6 months

          -  Qualified for chemotherapyï¼ŒWBC&gt;=3*109/L, ANC&gt;=1.5*109/L, Hb&gt;=80g/L, PLT&gt;=80*109/L.
             With no bleeding tendency or systemic hematology disorder symptoms.

          -  No obvious EKG abnormality, no obvious cardiac dysfunction, and normal left
             ventricular ejection fraction.

          -  Liver function, ALT and AST should less than 2.5 times of the upper limit.

          -  Renal function, Cr and BUN should less than 1.5 times of the upper limit.

          -  Subjects voluntarily participate in this study and sign informed consent.

        Exclusion Criteria:

          -  Total amount of doxorubicin used in previous chemotherapy&gt;240mg/m2, or
             epirubicin&gt;360mg/m2

          -  Has received hematopoietic stem cell transplantation or bone marrow transplantation

          -  Other drugs are currently in clinical trials

          -  There are currently hard-to-control infections, body temperature is higher than 38
             degrees.

          -  Received PEG-rhG-CSF treatment before enrollment

          -  Received chemotherapy in 4 weeks before enrollment

          -  Patients with any visceral metastasis

          -  Patients with severe heart, kidney, liver or any other important organs chronic
             diseases

          -  Patients with severe uncontrolled diabetes

          -  Patients with allergic diseases, or allergies to this product or other biological
             products derived from genetically engineered e. coli

          -  Suspected or real drug users, substance abusers, alcoholics

          -  Pregnant or lactating women

          -  Severe mental or neurological disorders that affect informed consent and adverse
             reactions described or observed
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Zhaoqing Fan</last_name>
    <phone>+86 13601052226</phone>
    <email>zhqfan@sina.com</email>
  </overall_contact>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>June 30, 2019</study_first_submitted>
  <study_first_submitted_qc>July 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 8, 2019</study_first_posted>
  <last_update_submitted>July 3, 2019</last_update_submitted>
  <last_update_submitted_qc>July 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University</investigator_affiliation>
    <investigator_full_name>Tao OUYANG</investigator_full_name>
    <investigator_title>chief of breast surgery</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neutropenia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

